Voyager Therapeutics (NASDAQ:VYGR) Price Target Cut to $7.00 by Analysts at Wedbush

Voyager Therapeutics (NASDAQ:VYGR) had its target price dropped by analysts at Wedbush from $8.00 to $7.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Wedbush’s price objective suggests a potential downside of 8.85% from the stock’s current price.

Several other research firms have also recently issued reports on VYGR. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Wednesday, July 31st. Finally, StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.83.

Voyager Therapeutics Stock Down 6.2 %

NASDAQ VYGR traded down $0.51 on Wednesday, hitting $7.68. 60,061 shares of the stock were exchanged, compared to its average volume of 683,230. Voyager Therapeutics has a fifty-two week low of $6.06 and a fifty-two week high of $11.72. The company has a market cap of $417.72 million, a PE ratio of -159.17 and a beta of 0.96. The company has a 50-day moving average price of $8.39 and a 200-day moving average price of $8.41.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.24. The firm had revenue of $19.52 million during the quarter, compared to the consensus estimate of $10.33 million. Voyager Therapeutics had a negative net margin of 2.56% and a negative return on equity of 1.28%. As a group, equities research analysts predict that Voyager Therapeutics will post -1.39 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC grew its position in Voyager Therapeutics by 1.4% in the fourth quarter. Armistice Capital LLC now owns 4,236,000 shares of the company’s stock valued at $35,752,000 after acquiring an additional 58,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after buying an additional 702,030 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Voyager Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Voyager Therapeutics by 10.1% during the first quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock valued at $4,280,000 after purchasing an additional 42,029 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.